Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07140679 · ClinicalTrials.gov registry record · Phase 2
Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer
A Phase 2 study of Stage III Colon Cancer AJCC V8 and Stage IIB Colon Cancer AJCC v8, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 5
- Study locations
NCT07140679 is a Phase 2 study of Stage III Colon Cancer AJCC V8 and Stage IIB Colon Cancer AJCC v8 that is actively recruiting participants, run by Emory University. The registered enrollment target is 40 participants, below the 139-participant average among 7 other Stage III Colon Cancer AJCC V8 trials with a reported enrollment target (71% lower). The trial reports 5 study locations across 1 state.
The verdict
NCT07140679, a Phase 2 study of Stage III Colon Cancer AJCC V8 and Stage IIB Colon Cancer AJCC v8, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 5
- Study locations
Study Summary
This phase II trial tests how well immunotherapy (toripalimab) works for reducing the risk of cancer recurrence after surgery in patients with mismatch repair deficient stage IIB, IIC, or III colon cancer.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Colonoscopy
- PROCEDURE Biopsy Procedure
- OTHER Questionnaire Administration
Study Locations (5)
Georgia
- Emory Decatur Hospital - Atlanta
- Emory University Hospital Midtown - Atlanta
- Emory University Hospital/Winship Cancer Institute - Atlanta
- Emory Saint Joseph's Hospital - Atlanta
- Emory Johns Creek Hospital - Johns Creek
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-09-19 |
| Est. Completion | 2029-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07140679
The ClinicalTrials.gov registry entry for NCT07140679 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 139-participant average among 7 other Stage III Colon Cancer AJCC V8 trials with a reported enrollment target (71% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Stage III Colon Cancer AJCC V8 appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT07140679 reports 5 study locations spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT07140679 about?
NCT07140679 is a clinical study titled "Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer". This phase II trial tests how well immunotherapy (toripalimab) works for reducing the risk of cancer recurrence after surgery in patients with mismatch repair deficient stage IIB, IIC, or III colon cancer.
What is the current status of trial NCT07140679?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-09-19. Estimated completion is 2029-12-31.
What conditions does trial NCT07140679 study?
This clinical trial studies the following conditions: Stage III Colon Cancer AJCC V8, Stage IIB Colon Cancer AJCC v8, Stage IIC Colon Cancer AJCC v8, Localized Colon Carcinoma.
What interventions are being tested in trial NCT07140679?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Colonoscopy (PROCEDURE), Biopsy Procedure (PROCEDURE), Questionnaire Administration (OTHER).
Who is sponsoring clinical trial NCT07140679?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07140679 being conducted?
This trial has 5 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage III Colon Cancer AJCC V8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
ACTIVE NOT RECRUITING · Phase 2
-
Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Designing a Dyad-Based MHealth Intervention to Improve Adherence to Lifestyle Recommendations in Colorectal Cancer Survivors and Their Family Caregivers
RECRUITING · NA
-
SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial
ACTIVE NOT RECRUITING · Phase 1
-
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.